Quantcast

Latest Visual acuity Stories

2009-06-02 10:00:00

InfantSEE(R) reminds parents about the importance of eye assessments for babies during June's Child Vision Awareness Month ST. LOUIS, June 2 /PRNewswire/ -- When should a parent schedule a comprehensive eye assessment for a baby? Clinical research has shown that at 6 months, the average baby has reached a number of critical developmental milestones, making this an appropriate age for the first eye and vision assessment. According to the American Optometric Association's (AOA) 2008 American...

2009-05-28 07:32:00

LINCOLN, R.I., May 28 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc. today announced that the Company's product candidate, NT-501, demonstrated a strong biologic effect in two Phase 2 clinical trials for retinitis pigmentosa (RP). RP is a slowly developing condition that causes the progressive degeneration of rod & cone photoreceptor cells in the retina that over time diminishes night and peripheral vision and eventually leads to blindness. RP is an orphan-designated indication for which...

2008-12-16 06:30:00

Mean visual acuity letter scores increased similarly in all treatment groups VANCOUVER, Dec. 16 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) today announced six-month results from an interim analysis for the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions). The RADICAL study is a Phase II, multicenter, randomized, single-masked study comparing reduced-fluence Visudyne(R)-Lucentis(R) combination therapies (with or...

2008-11-05 18:00:23

SARATOGA, Calif., Nov. 5 /PRNewswire/ -- VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices for individuals with age-related macular degeneration (AMD), today announced that the American Journal of Ophthalmology (AJO), a premier peer-reviewed medical journal, has published two-year results from the Phase II/III IMT002 trial showing substantial visual acuity improvement in End-Stage AMD patients. The study device, a first-of-kind implantable telescope,...

2008-10-15 00:00:05

Visual impairment appears to be more common in people with diabetes than in those without the disease, U.S. researchers say. Dr. Xinzhi Zhang and colleagues at the Centers for Disease Control and Prevention in Atlanta used data from the National Health and Nutrition Examination Surveys from 1999 to 2004, which included 1,237 adults with diabetes -- average age 59 -- and 11,767 adults without the disease -- average age 45. The study particpants' visual acuity was measured before and after...

2008-09-29 12:00:41

Regeneron Pharmaceuticals and Bayer HealthCare have announced that VEGF Trap-Eye achieved durable improvements in visual acuity and in biologic measures of neovascular disease, including retinal thickness and active choroidal neovascularization lesion size, for up to one year in a Phase II study in the neovascular form of age-related macular degeneration. In this double-masked Phase II trial, patients were initially treated with either fixed monthly or quarterly dosing for 12 weeks and then...

2008-09-28 15:00:33

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare AG announced that VEGF Trap-Eye achieved durable improvements in visual acuity and in biologic measures of neovascular disease, including retinal thickness and active choroidal neovascularization lesion size, for up to one year in a Phase 2 study in the neovascular form of Age-related Macular Degeneration (wet AMD). The results were reported today in two oral presentations at the 2008 annual meeting of the Retina Society in...

2008-09-10 09:00:48

HOUSTON, Sept. 10 /PRNewswire/ -- A landmark study at five university-based research centers found that TOZAL(R), a patented combination of antioxidants and micronutrients, enabled patients with "dry" macular degeneration to improve their vision. Patients in the study's placebo arm, who received the "AREDS-type" nutritional formulation (the current standard of care), continued to lose their eyesight. Results of the TOZAL study are supported by a major new study, which shows that omega-3...

2008-09-04 12:00:33

Neurotech Pharmaceuticals, a biotechnology company focused on the development of sight-saving therapeutics for chronic retinal diseases, has announced that the FDA has granted fast track designations for NT-501 for the treatment of visual loss in two indications - retinitis pigmentosa and the dry form of age-related macular degeneration. Neurotech is conducting two Phase II/III trials of NT-501 for the treatment of visual loss associated with retinitis pigmentosa (RP)-one consisting of...

2008-09-02 12:00:00

Doctors and medical centers across the United States are debating the use of electronic health records (EHR). This month's Ophthalmology, the journal of the American Academy of Ophthalmology, provides a look at Eye M.D.s' actions and opinions on the issue. Also highlighted this month are two research studies that will help doctors identify patients who are most vulnerable to advanced age-related macular degeneration (AMD), the leading cause of severe vision loss in the United States and most...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.